Mindwalk Holdings Corp

MindWalk reported revenue of CAD 3.8m (+21%) for Q1 FY2027 and an improved gross margin of 59% thanks to a better product mix. The net loss from continuing operations increased to CAD 6.1m, driven by sharply higher sales, marketing and product development expenses. Management highlights progress commercializing the data platform ReefIQ and is in talks with several large pharma companies, but gives no timeline for contract wins. The company secured a CAD 30m revolving credit facility to preserve financial flexibility, while cash burn and limited revenue visibility remain the main risks. » More on de.investing.com

MindWalk has received a binding commitment from Sanabil (Cayman) for an unsecured revolving credit facility of up to USD 30 million at a fixed interest rate of 7.0% p.a. The initial term is 36 months with an optional 12‑month extension; there are no financial covenants, warrants, conversion rights or pledging of assets. MindWalk will pay a one‑time commitment fee of 1.0% and plans to use the proceeds for biologics programs, commercial expansion, working capital and general corporate purposes. The binding term sheet is to be converted into a final loan agreement within 60 days and filed as a material contract. » More on de.investing.com

MindWalk will release results for the quarter ended July 31, 2026 on September 14, 2026 at a financial conference. Three analysts forecast an average EPS of -0.077 CAD per share versus -0.050 USD a year ago and quarterly revenue averaging 4.5 million CAD versus 2.3 million USD in the year-ago quarter. For the current fiscal year, analysts on average expect a loss per share of -0.313 CAD and annual revenue of 20.3 million CAD versus 11.3 million USD last year. » More on finanzen.net